DVAX Overzicht aandelen
Dynavax Technologies Corporation, een biofarmaceutisch bedrijf in een commerciële fase, richt zich op de ontwikkeling en commercialisering van vaccins in de Verenigde Staten.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Dynavax Technologies Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$11.78 |
| 52 Week Hoogtepunt | US$15.01 |
| 52 Week Laag | US$9.74 |
| Bèta | 1.37 |
| 11 maand verandering | 6.90% |
| 3 maanden verandering | 17.21% |
| 1 Jaar Verandering | -12.81% |
| 33 jaar verandering | -26.97% |
| 5 jaar verandering | 108.13% |
| Verandering sinds IPO | -87.47% |
Recent nieuws en updates
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Oct 12
Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14Recent updates
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Oct 12Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Dynavax: A Coronavirus Growth Story
Jan 17Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 18The Momentum Investor: Spotlight On Dynavax Technologies
Oct 25Rendement voor aandeelhouders
| DVAX | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 3.4% | -0.7% | -1.6% |
| 1Y | -12.8% | 19.8% | 30.8% |
Rendement versus industrie: DVAX underperformed the US Biotechs industry which returned 19.8% over the past year.
Rendement versus markt: DVAX underperformed the US Market which returned 30.8% over the past year.
Prijsvolatiliteit
| DVAX volatility | |
|---|---|
| DVAX Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: DVAX has not had significant price volatility in the past 3 months compared to the US market.
Volatiliteit in de loop van de tijd: DVAX's weekly volatility (5%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1996 | 408 | Ryan Spencer | www.dynavax.com |
Dynavax Technologies Corporation, een biofarmaceutisch bedrijf in de commerciële fase, richt zich op de ontwikkeling en commercialisering van vaccins in de Verenigde Staten. Het bedrijf brengt HEPLISAV-B op de markt, een hepatitis B-vaccin voor de preventie van infectie veroorzaakt door alle bekende subtypes van het hepatitis B-virus bij personen van 18 jaar en ouder in de Verenigde Staten en Europa. Het bedrijf produceert en verkoopt ook CpG 1018, het hulpstof dat wordt gebruikt in HEPLISAV-B.
Dynavax Technologies Corporation Samenvatting
| DVAX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.54b |
| Inkomsten(TTM) | US$17.18m |
| Inkomsten(TTM) | US$249.69m |
89.9x
Koers/Winstverhouding6.2x
P/S-verhoudingIs DVAX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| DVAX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$249.69m |
| Kosten van inkomsten | US$98.80m |
| Brutowinst | US$150.90m |
| Overige uitgaven | US$133.72m |
| Inkomsten | US$17.18m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
Nov 07, 2024
| Winst per aandeel (EPS) | 0.13 |
| Brutomarge | 60.43% |
| Nettowinstmarge | 6.88% |
| Schuld/Eigen Vermogen Verhouding | 34.7% |
Hoe presteerde DVAX op de lange termijn?
Bekijk historische prestaties en vergelijking